Physician profile
Arthur E Okere
NPI 1790928612
$10,299.18
in general payments reported to CMS, 2019-2025
40 companies · $1,751 in 2025
The $1,751 reported for 2025 was more than what 81% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,695 · 2020: $984 · 2021: $2,047 · 2022: $840 · 2023: $1,403 · 2024: $1,580 · 2025: $1,751.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,723 · Education: $10.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,722.90 |
| Education | $10.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,022.89 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Mitraclip, Diamondback Peripheral |
| Astrazeneca Pharmaceuticals Lp | $1,178.24 | 2019-2025 | Farxiga, Lynparza |
| Novartis Pharmaceuticals Corporation | $756.61 | 2019-2025 | |
| Abiomed | $647.91 | 2021-2025 | Impella |
| E.R. Squibb & Sons, L.L.C. | $517.11 | 2019-2025 | Eliquis, Camzyos |
| Amgen INC. | $512.32 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $468.14 | 2019-2024 | Xarelto |
| Pfizer INC. | $430.37 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $339.20 | 2021-2025 | Jardiance |
| Medtronic, INC. | $310.90 | 2024-2025 | Symplicity G3, Onyx Frontier |
| Merck Sharp & Dohme LLC | $289.35 | 2021-2025 | Verquvo, Capvaxive |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $271.06 | 2019-2025 | Lifevest |
| Cvrx, INC. | $183.54 | 2023-2024 | Barostim Neo System |
| Ge Healthcare | $168.24 | 2019 | |
| Tactile Systems Technology INC | $129.65 | 2020 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthur Okere listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.